Crossject Société Anonyme (EPA:ALCJ) On The Verge Of Breaking Even

Crossject Société Anonyme (EPA:ALCJ) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Crossject Société Anonyme develops needle-free injection systems in France. The €82m market-cap company posted a loss in its most recent financial year of €8.6m and a latest trailing-twelve-month loss of €10m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Crossject Société Anonyme's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

Check out our latest analysis for Crossject Société Anonyme

Expectations from some of the French Medical Equipment analysts is that Crossject Société Anonyme is on the verge of breakeven. They expect the company to post a final loss in 2024, before turning a profit of €23m in 2025. So, the company is predicted to breakeven approximately a year from now or less! We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 102% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Crossject Société Anonyme given that this is a high-level summary, however, bear in mind that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

One thing we would like to bring into light with Crossject Société Anonyme is it currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are too many aspects of Crossject Société Anonyme to cover in one brief article, but the key fundamentals for the company can all be found in one place – Crossject Société Anonyme's company page on Simply Wall St. We've also put together a list of important aspects you should further examine:

1. Valuation: What is Crossject Société Anonyme worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Crossject Société Anonyme is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Crossject Société Anonyme’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.